aTYR PHARMA (ATYR) Equity Average (2019 - 2025)
aTYR PHARMA (ATYR) has disclosed Equity Average for 7 consecutive years, with $73.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 9.44% year-over-year to $73.9 million, compared with a TTM value of $73.9 million through Dec 2025, up 9.44%, and an annual FY2025 reading of $68.7 million, down 14.34% over the prior year.
- Equity Average was $73.9 million for Q4 2025 at aTYR PHARMA, down from $77.4 million in the prior quarter.
- Across five years, Equity Average topped out at $113.3 million in Q4 2021 and bottomed at $40.5 million in Q1 2021.
- Average Equity Average over 5 years is $81.7 million, with a median of $80.4 million recorded in 2021.
- The sharpest move saw Equity Average surged 256.9% in 2021, then crashed 34.55% in 2022.
- Year by year, Equity Average stood at $113.3 million in 2021, then plummeted by 34.55% to $74.1 million in 2022, then increased by 27.23% to $94.3 million in 2023, then decreased by 28.46% to $67.5 million in 2024, then rose by 9.44% to $73.9 million in 2025.
- Business Quant data shows Equity Average for ATYR at $73.9 million in Q4 2025, $77.4 million in Q3 2025, and $74.8 million in Q2 2025.